Maciej Banach: Emerging Triglyceride Targeted Therapies in MASLD and Liver Disease
Maciej Banach, Vice-Rector for the Collegium Medicum at John Paul II Catholic University of Lublin, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Please see our recent hot topic review on ‘Triglyceride-lowering therapies for hepatic steatosis’ just accepted for the Frontiers in Pharmacology journal with Seyed Saeed Tamehri Zadeh and Peter P. Toth.
Hepatic steatosis, the hallmark of MASLD, is closely associated with elevated plasma and intrahepatic triglyceride (TG) levels, often driven by insulin resistance, atherogenic dyslipidemia, and metabolic syndrome.
Growing evidence suggests that triglyceride-lowering therapies may not only improve systemic lipid profiles but also directly impact hepatic fat accumulation and associated inflammation and fibrosis.
This review explores current and emerging TG-lowering therapies, including fibrates, omega3 fatty acids, and novel agents such as pegozafermin (an FGF21 analog), and APOC3 and angiopoietin-like protein 3 (ANGPTL3) inhibitors, in the context of hepatic steatosis and MASLD.
We discuss the mechanistic rationale behind TG-lowering as a therapeutic strategy, summarize key preclinical and clinical trial findings, and evaluate their effects on liver fat content, liver enzymes, fibrosis markers, and histologic outcomes.
While several agents demonstrate promise in reducing intrahepatic fat deposition and improving liver-related outcomes, further large-scale studies are required to establish their long-term efficacy and safety, and potential for disease modification in MASLD/MASH.
Triglyceride-targeted therapies may offer a valuable adjunct or complementary approach to current treatment paradigms focused on weight loss, insulin sensitization, and antagonizing inflammation.
The preprint version is available․”
Title: Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives
Author: Seyed Saeed Tamehri Zadeh, Peter Paul Toth, Maciej Banach
Other posts featuring Maciej Banach on Hemostasis Today.
-
Apr 18, 2026, 12:21Sarah Richardson: I’m Proud to Advocate for My Hemo Hero, for Myself, and for The Entire Community
-
Apr 18, 2026, 11:33Standing Together for Patients with Bleeding Disorders – ISTH
-
Apr 18, 2026, 11:21Gianluca Franceschini: Immersive Virtual Reality in Preoperative Care
-
Apr 18, 2026, 10:58Jean Jacques Kiladjian: Honored to Join the HST EHA Session at the Taiwan Annual Meeting
-
Apr 18, 2026, 10:49Advancing Diagnosis to Improve Lives in Hemophilia – WFH
-
Apr 18, 2026, 10:40Akshat Jain: Improving Treatment and Access for Patients with Bleeding Disorders
-
Apr 18, 2026, 10:24Sonia Wolf: Barts Health Presence at BSH with Multiple Presentations and Awards
-
Apr 18, 2026, 10:22Cathy Harrison: The Central Role of Diagnosis in Bleeding Disorders Management
-
Apr 18, 2026, 10:10Rich Gorman: Understanding Lived Experience in Bleeding Disorders Through Arts-Based Research